Xontogeny
Bradley Murray is a seasoned professional in the biotech sector, currently serving as CEO and Co-Founder of Delve Bio since October 2022, where the focus is on enhancing precision medicine through advanced genomic technology. Prior to this role, Bradley has been involved with Xontogeny as an advisor since October 2020 and held various positions at Intellia Therapeutics, Inc. from December 2015 to October 2020, progressing from Associate Computational Scientist to Manager. Earlier experience includes a role as Associate Computational Biologist at the Broad Institute from July 2013 to December 2015 and an internship at Vertex Pharmaceuticals in 2012. Bradley holds a Bachelor of Science in Biology from Georgetown University and an MBA in Finance from Boston College Carroll School of Management.